Versanis Bio secured $70 to commercialise a treatment licensed from Novartis, while Salesforce, Intel, Orange, Nike and Alphabet all celebrated exits.

Funding

Versanis Bio, a US-based developer a treatment for metabolic disease and obesity, completed a $70m series A round yesterday co-led by Atlas Venture and Medicxi, with participation from Aditum Bio. The latter established Versanis Bio with an undisclosed amount of seed financing to commercialise a therapy called bimagrumab that was in-licensed from pharmaceutical firm Novartis.

Japan-based virtual currency exchange Bitbank has raised ¥7.5bn ($68.2m) led by internet company Mixi, which provided $63.6m, while digital media group Ceres supplied the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn